Literature DB >> 32755310

The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Shelley E Harris1, Toryn M Poolman1, Anastasia Arvaniti1,2, Roger D Cox3, Laura L Gathercole1,2, Jeremy W Tomlinson1.   

Abstract

The pathogenesis of nonalcoholic fatty liver disease (NAFLD) and the progression to nonalcoholic steatohepatitis (NASH) and increased risk of hepatocellular carcinoma remain poorly understood. Additionally, there is increasing recognition of the extrahepatic manifestations associated with NAFLD and NASH. We demonstrate that intervention with the American lifestyle-induced obesity syndrome (ALIOS) diet in male and female mice recapitulates many of the clinical and transcriptomic features of human NAFLD and NASH. Male and female C57BL/6N mice were fed either normal chow (NC) or ALIOS from 11 to 52 wk and underwent comprehensive metabolic analysis throughout the duration of the study. From 26 wk, ALIOS-fed mice developed features of hepatic steatosis, inflammation, and fibrosis. ALIOS-fed mice also had an increased incidence of hepatic tumors at 52 wk compared with those fed NC. Hepatic transcriptomic analysis revealed alterations in multiple genes associated with inflammation and tissue repair in ALIOS-fed mice. Ingenuity Pathway Analysis confirmed dysregulation of metabolic pathways as well as those associated with liver disease and cancer. In parallel the development of a robust hepatic phenotype, ALIOS-fed mice displayed many of the extrahepatic manifestations of NAFLD, including hyperlipidemia, increased fat mass, sarcopenia, and insulin resistance. The ALIOS diet in mice recapitulates many of the clinical features of NAFLD and, therefore, represents a robust and reproducible model for investigating the pathogenesis of NAFLD and its progression.NEW & NOTEWORTHY Nonalcoholic fatty liver disease (NAFLD) affects 30% of the general population and can progress to nonalcoholic steatohepatitis (NASH) and potentially hepatocellular carcinoma. Preclinical models rely on mouse models that often display hepatic characteristics of NAFLD but rarely progress to NASH and seldom depict the multisystem effects of the disease. We have conducted comprehensive metabolic analysis of both male and female mice consuming a Western diet of trans fats and sugar, focusing on both their hepatic phenotype and extrahepatic manifestations.

Entities:  

Keywords:  diet; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; transcriptome

Mesh:

Substances:

Year:  2020        PMID: 32755310      PMCID: PMC7509261          DOI: 10.1152/ajpgi.00055.2020

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  52 in total

1.  The Applicability of a Human Immunohistochemical Panel to Mouse Models of Hepatocellular Neoplasia.

Authors:  Kenneth J Salleng; Frank L Revetta; Natasha G Deane; M Kay Washington
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

2.  Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.

Authors:  Ju Dong Yang; Fowsiyo Ahmed; Kristin C Mara; Benyam D Addissie; Alina M Allen; Gregory J Gores; Lewis R Roberts
Journal:  Hepatology       Date:  2019-10-21       Impact factor: 17.425

3.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

4.  A Mouse Model of Metabolic Syndrome: Insulin Resistance, Fatty Liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 Mice Fed a High Fat Diet.

Authors:  Julio C Fraulob; Rebeca Ogg-Diamantino; Caroline Fernandes-Santos; Marcia Barbosa Aguila; Carlos A Mandarim-de-Lacerda
Journal:  J Clin Biochem Nutr       Date:  2010-04-10       Impact factor: 3.114

5.  Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.

Authors:  Janice M Paterson; Nicholas M Morton; Catherine Fievet; Christopher J Kenyon; Megan C Holmes; Bart Staels; Jonathan R Seckl; John J Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

6.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

7.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Authors:  Lisa B VanWagner; Mary E Rinella
Journal:  Curr Hepatol Rep       Date:  2016-03-28

8.  Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice.

Authors:  Helene L Kammoun; Tamara Louise Allen; Darren Colin Henstridge; Michael James Kraakman; Lone Peijs; Stefan Rose-John; Mark Anthony Febbraio
Journal:  PLoS One       Date:  2017-06-20       Impact factor: 3.240

9.  Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease.

Authors:  Goh Eun Chung; Min Joo Kim; Jeong Yoon Yim; Joo Sung Kim; Ji Won Yoon
Journal:  J Obes Metab Syndr       Date:  2019-06-30

10.  Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.

Authors:  Joanna K Dowman; Laurence J Hopkins; Gary M Reynolds; Nikolaos Nikolaou; Matthew J Armstrong; Jean C Shaw; Diarmaid D Houlihan; Patricia F Lalor; Jeremy W Tomlinson; Stefan G Hübscher; Philip N Newsome
Journal:  Am J Pathol       Date:  2014-03-17       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.